think research ltd

Cookies on Companies House services

We use some essential cookies to make our services work.

We'd also like to use analytics cookies so we can understand how you use our services and to make improvements.

You've accepted analytics cookies. You can change your cookie settings at any time.

You've rejected analytics cookies. You can change your cookie settings at any time.

We use cookies to make our services work and collect analytics information. To accept or reject analytics cookies, turn on JavaScript in your browser settings and reload this page.

Please press ENTER to search

THINK RESEARCH LIMITED

Company number 05073914

• Company Overview for THINK RESEARCH LIMITED (05073914)
• Filing history for THINK RESEARCH LIMITED (05073914)
• People for THINK RESEARCH LIMITED (05073914)
• Charges for THINK RESEARCH LIMITED (05073914)
• More for THINK RESEARCH LIMITED (05073914)

Next accounts made up to 31 March 2024 due by 31 December 2024

Last accounts made up to 31 March 2023

Confirmation statement

Next statement date 31 March 2025 due by 14 April 2025

Last statement dated 31 March 2024

Nature of business (SIC)

• 74909 - Other professional, scientific and technical activities not elsewhere classified

We cut through the fog of traditional ATM research, development and implementation to get to the core of the issues. 

At Think Research we don’t try and use smoke and mirrors to make the issue (and therefore our role in helping) as complicated as possible. In fact, we will work to make it appear as simple and understandable as possible.

We will aim to Crystallise your Objectives, Simplify the Complexity of the challenges and Apply Innovation in delivering a Solution.

We constantly question ourselves to make sure we are doing the best job we possibly can. If there is a better way of doing something, we will find it. If there is a better answer for the client, we will come up with it.

WHAT MAKES US DIFFERENT TO OTHER AVIATION CONSULTANTS?

We could just say we are not like other consultancies, but that’s what all consultancies say!

We accept that the type of work we do and the projects we are involved in might be the same as other consultancies – we don’t try and say otherwise.

Our services differ from those you would find in other consultancies, with our wide range of operational expertise, supported by simulation and innovation and tied together through a well-defined validation methodology.

Most importantly, the way in which we conduct ourselves as consultancy and as people is totally different. We are the modern consultancy with old fashioned virtues. We believe in transparency, simplicity, clarity, honesty and value.

We are built on being the best we can be – for our clients and for ourselves.

We are built on being Quicker; Better; Cheaper

Privacy Overview

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Newsletters
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• The Morning Brief
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds Rates
• Top Mutual Funds
• Options: Highest Open Interest
• Options: Highest Implied Volatility
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Screeners Beta
• Stock Comparison
• Advanced Chart
• Currency Converter
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Credit Card Offers
• Best Free Checking
• Student Loans
• Personal Loans
• Car insurance
• Mortgage Refinancing
• Mortgage Calculator
• Editor's Picks
• Investing Insights
• Trending Stocks
• Morning Brief
• Opening Bid
• Streaming Now
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Think Research Enters into Definitive Agreement to be Acquired by Beedie Capital

• Think Research Corporation shareholders to receive cash payment of $0.32 per Common Share, representing a 100% premium to the closing price of the Common Shares on February 15, 2024 and a 75% premium to the 30-day volume-weighted average trading price of the Common Shares • Special Committee and Board (excluding any interested directors) unanimously determined the Transaction is in the best interests of the Company, and the Board (excluding any interested directors) has recommended that shareholders vote in favour of the Transaction • Certain shareholders, including Chief Executive Officer, Sachin Aggarwal, to roll their equity ownership • Shareholders holding 48.21% of the Common Shares have agreed to support the Transaction • Think Research Corporation will continue to execute on its strategy of delivering knowledge-based digital health software solutions as a private company upon the completion of the Transaction

TORONTO, ON / ACCESSWIRE / February 16, 2024 / Think Research Corporation (TSXV:THNK) (" Think " or the " Company "), a company focused on transforming healthcare through digital health software solutions, today announced that it has entered into an arrangement agreement (the " Arrangement Agreement ") with Beedie Investments Ltd. (" Beedie Capital "), a multi-strategy direct investment platform managing alternative investments for one of the largest private companies in Western Canada, pursuant to which Beedie Capital will acquire all of the common shares in the capital of the Company (the " Shares "), other than those Shares owned by Beedie Capital and other shareholders comprised of certain directors and executive officers of the Company as well as other persons (such shareholders, collectively, the " Continuing Shareholders "), for cash consideration of $0.32 per Share (the " Consideration ") (collectively, the " Transaction "). The Consideration represents a 100% premium to the closing price of the Shares on the TSX Venture Exchange (the " TSXV ") on February 15, 2024, the last trading day immediately prior to the announcement of the Transaction, and a 75% premium to the 30-day volume-weighted average price (" VWAP ") of the Shares on the TSXV for the period ended February 15, 2024. As of the date hereof, the Continuing Shareholders, collectively, beneficially own or control an aggregate of 21,706,567 Shares (representing approximately 27.4% of the issued and outstanding Shares on a non-diluted basis).

"The Think team is pleased that Beedie Capital has demonstrated its confidence in the Company through this Transaction, the Consideration of which reflects a strong endorsement of the Company's value. Beedie Capital has a deep understanding of our business and we look forward to working with them to continue executing on our plan to accelerate growth and provide digital solutions to clinicians worldwide," said Think Research's Chief Executive Officer, Sachin Aggarwal. "In addition, the Transaction eliminates the financial and administrative burden of continuing as a reporting issuer in what is already a challenging market environment."

Richard Wells, an independent director of the Think board of directors (the " Board ") and Chair of the Special Committee, said, "After a comprehensive process and careful deliberation, supported by external professional advisors, the Special Committee considers that the Transaction represents the best available path forward for the Company, its shareholders, lenders, employees and other stakeholders. This Transaction provides a cash premium and immediate liquidity to holders of Shares and the Board is unanimous in its belief that this Transaction is in the best interests of all Think shareholders."

Special Committee and Board Recommendations

The Arrangement Agreement was approved unanimously by the Board (with any interested director abstaining from voting due to his or her participation in the Transaction as a Continuing Shareholder), after taking into account, among other things, the unanimous recommendation of a special committee (the " Special Committee ") of the Board comprised of Richard Wells, Cindy Gray and Jeffrey Orridge, each an independent director of the Company. The Special Committee and the Board (with the abstention of any interested directors) determined that the Transaction is in the best interests of the Company and the Board recommends that holders of Shares (other than Beedie Capital and the Continuing Shareholders) vote in favour of the Transaction at the Meeting (as defined below).

In making its determination to unanimously recommend approval of the Transaction to the Board, and in the Board's determination to approve the Transaction, the Special Committee and the Board considered the following factors, among other things:

• Compelling Value and Immediate Liquidity - the all-cash Consideration provides shareholders with immediate value and is of particular benefit given the limited trading volume, the financial challenges facing the Company and the lack of liquidity in the Shares. The Consideration represents a 100% premium to the closing price of the Shares on the TSXV on February 15, 2024, the last trading day immediately prior to the announcement of the Transaction, and a 75% premium to the 30-day VWAP of the Shares on the TSXV for the period ended February 15, 2024; • Fairness Opinion - the Special Committee received an oral fairness opinion from Canaccord Genuity Corp. ("Canaccord"), which opinion concluded that, based upon and subject to the assumptions made, procedures followed, matters considered, limitations and qualifications set out therein, the Consideration to be received by the shareholders (other than Beedie Capital and the Continuing Shareholders) pursuant to the Transaction is fair, from a financial point of view, to the shareholders. A written copy of the fairness opinion will be included in the materials sent to shareholders in connection with the Meeting; • Go-Shop Provision - the Arrangement Agreement includes a go-shop provision, during which time the Company, with the assistance of Canaccord, will be permitted to actively solicit, evaluate and enter into negotiations with respect to a potential Superior Proposal (as defined in the Arrangement Agreement) for a 30-day period, as more particularly described below; • Support for the Transaction - each of the Continuing Shareholders and certain other shareholders, directors that hold Shares and certain officers of the Company has entered into a voting support agreement, pursuant to which they have agreed to, among other things, vote their Shares, which represent approximately 48.21% of all of the Shares, in favour of the Transaction at the Meeting; • Arrangement Agreement and "Fiduciary Out" - the Arrangement Agreement is the result of a comprehensive negotiation process that was supervised by the Special Committee, as advised by independent and highly qualified legal and financial advisors, and resulted in terms and conditions that are reasonable in the judgment of the Special Committee and the Board, including a customary "fiduciary out" that will enable the Company to enter into a Superior Proposal in certain circumstances; • Break Fee - the break fee payable by the Company equal to $1,065,943 is reasonable in the circumstances and only payable in customary and limited circumstances; and • Minority Vote and Court Approval - the Transaction must be approved not only by at least two-thirds (66⅔%) of the votes cast by shareholders, but also by a majority of the minority in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"), and by the Ontario Superior Court of Justice (Commercial List).

Transaction Details

Pursuant to the terms of the Arrangement Agreement, Beedie Capital will acquire all of the Shares, other than those Shares owned by Beedie Capital and the Continuing Shareholders, for a purchase price of $0.32 per Share, payable in cash. The Transaction is to be effected by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) and is expected to close in the second quarter of 2024, subject to shareholder, court and regulatory approvals and other closing conditions customary to transactions of this nature. Completion of the Transaction is not subject to any financing condition.

The Arrangement Agreement includes a go-shop period extending until March 16, 2024 (the " Go-Shop Period "), during which time the Company, with the assistance of Canaccord, will, subject to the requirements and limitations set forth in the Arrangement Agreement, be permitted to actively solicit, evaluate and enter into negotiations with third parties that express an interest in acquiring the Company with a view to obtaining a potential Superior Proposal. Following the expiry of the Go-Shop Period, the Company will be subject to customary non-solicitation covenants with customary "fiduciary out" provisions that entitle the Special Committee and the Board to consider and, subject to certain conditions, accept a Superior Proposal if Beedie Capital does not match such Superior Proposal. If the Arrangement Agreement is terminated under certain circumstances, including circumstances in which the Company terminates the Arrangement Agreement to accept a Superior Proposal prior to approval of the Transaction by shareholders, a termination fee equal to $1,065,943 is payable by the Company to Beedie Capital. There can be no assurance that a Superior Proposal will be made as a result of the go-shop process or otherwise, and the Company does not intend to disclose developments with respect to the go-shop process or any interest received by third parties during the Go-Shop Period, unless and until the Special Committee and the Board make a determination requiring further disclosure.

A special meeting of holders of Shares to consider and, if deemed advisable, approve the Transaction (the " Meeting ") is expected to be held in early April 2024. In order to be approved by holders of Shares at the Meeting, the Transaction will require the approval of: (a) at least two-thirds (66 ⅔%) of the votes cast at the Meeting in person or by proxy by holders of Shares; and (b) a simple majority of the votes cast at the Meeting in person or by proxy by holders of Shares (other than Shares required to be excluded under MI 61-101 and applicable TSXV rules).

Additional details regarding the Transaction, the background to the Transaction, the reasons for the Board and Special Committee's recommendations of the Transaction, and how Company shareholders can participate in and vote at the Meeting, will be set out in the Company's management information circular and other proxy-related materials to be prepared, filed and sent to the Company's shareholders in connection with the Meeting. Copies of the Arrangement Agreement and the management information circular for the Meeting will be filed with Canadian securities regulators and will be made available on the SEDAR+ profile of the Company at www.sedarplus.ca . Shareholders of the Company are urged to read those and other relevant materials when they become available. Upon closing of the Arrangement, the Purchaser intends to cause the Shares to be delisted from the TSXV and will submit an application to cease to be a reporting issuer under applicable Canadian securities laws.

Voting Support Agreements

In connection with the Transaction, the Continuing Shareholders and certain other shareholders, and all directors who hold Shares and certain officers of the Company, who hold, in aggregate, 38,194,731 Shares (representing approximately 48.21% of the issued and outstanding Shares (on a non-diluted basis)), have entered into voting support agreements with Beedie Capital, providing for such shareholders to vote all Shares owned by them in favour of the Transaction.

Canaccord Genuity Corp. is acting as financial advisor to the Special Committee. Cassels Brock & Blackwell LLP is acting as independent legal advisor to the Special Committee. Stikeman Elliott LLP is acting as legal advisor to the Company.

Dentons Canada LLP is acting as legal advisor to Beedie Capital.

Early Warning Information

In connection with the Arrangement Agreement, in addition to the voting support agreement described above, Beedie Capital and the Continuing Shareholders have entered into a framework agreement dated as of the date hereof, which sets forth certain covenants and agreements between Beedie Capital and the Continuing Shareholders as it relates to the Transaction, the Shares held by the Continuing Shareholders and the relationship of such parties immediately following closing of the Transaction. It is intended that, immediately following the Transaction, the Company will make an application to cease to be a reporting issuer under Canadian securities law.

Both immediately before and immediately after the execution of the Arrangement Agreement, Beedie Capital held or exercised control or direction over (i) 2,934,900 Shares, representing approximately 3.7% of the issued and outstanding Shares (on a non-diluted basis), (ii) assuming the conversion in full of the aggregate principal amount outstanding under the non-revolving term convertible loan facility made available by Beedie Capital to the Company (the " Convertible Loan ") of $21 million using the applicable conversion price as of the respective dates of each advance under the Convertible Loan, an aggregate of 43,078,065 Shares, representing approximately 36.1% of the issued and outstanding Shares (on a partially-diluted basis), and (iii) assuming the conversion in full of the principal amounts outstanding under the Convertible Loan together with the remaining $4 million of subsequent advances thereunder at a conversion price of $0.20 per share, representing a 25% premium above the closing price of the Shares on the TSXVas of February 15, 2024, an aggregate of 63,039,057 Shares, representing approximately 45.25% of the issued and outstanding Shares (on a partially-diluted basis). Following the completion of the Transaction, Beedie Capital will own approximately 72.6% of the issued and outstanding Shares.

An early warning report will be filed by Beedie Capital in accordance with applicable securities laws and will be available on SEDAR+ at www.sedarplus.ca or may be obtained directly from Beedie Capital upon request at 604-436-7888. Beedie Capital's head office is located at Suite 900 - 1111 West Georgia St., Vancouver, BC, V6E 4M3.

Forward Looking Information

This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information may be identified by statements including words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could,", "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and the conditional.

Statements including forward-looking information may include, without limitation, statements regarding the rationale of the Special Committee and the Board for entering into the Arrangement Agreement, the expected benefits of the Transaction, the timing of various steps to be completed in connection with the Transaction, and other statements that are not material facts. Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to, that the parties will receive, in a timely manner and on satisfactory terms, the necessary court, shareholder and regulatory approvals, and that the parties will otherwise be able to satisfy, in a timely manner, the other conditions to the closing of the Transaction. The Company considers these assumptions to be reasonable in the circumstances. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. By its nature, forward-looking information involves known and unknown risks, uncertainties, changes in circumstances and other factors that are difficult to predict and many of which are outside of the Company's control which may cause actual results to differ materially from the any future or potential results expressed or implied by such forward-looking information. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, (i) the possibility that the Transaction will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, required shareholder, regulatory and court approvals and other conditions of closing necessary to complete the Transaction or for other reasons; (ii) the possibility of adverse reactions or changes in business resulting from the announcement or completion of the Transaction; (iii) risks relating to the Company's ability to retain and attract key personnel during the interim period; (iv) the possibility of litigation relating to the Transaction; (v) the potential of a third party making a Superior Proposal; (v) risks related to diverting management's attention from the Company's ongoing business operations; and (vi) other risks inherent to the business carried out by the Company and factors beyond its control which could have a material adverse effect on the Company or its ability to complete the Transaction. The Company has assumed that the risk factors referred to above will not cause such forward-looking statements and information to differ materially from actual results or events. The reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements.

Other than as specifically required by applicable Canadian law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made, whether as a result of new information, future events or results, or otherwise.

About Think Research Corporation

Think Research Corporation is an industry leader in delivering knowledge-based digital health software solutions. The Company's focused mission is to organize the world's health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process and standardization of care to facilitate better health care outcomes. The Company gathers, develops, and delivers knowledge-based solutions globally to customers including enterprise clients, hospitals, health regions, healthcare professionals, and / or governments. The Company has gathered a significant amount of data by building its repository of knowledge through its network and group of companies.

The Company licenses its solutions to over 14,200 facilities for over 320,000 primary care, acute care, and long-term care doctors, nurses and pharmacists that rely on the content and data provided by the Company to support their practices. Millions of patients and residents annually receive better care due to the essential data that the Company produces, manages and delivers.

In addition, the Company collects and manages pharmaceutical and clinical trial data via its BioPharma Services subsidiary. BioPharma Services is a leading provider of bioequivalence and Phase 1 clinical research services to pharmaceutical companies globally. The Company's other services include a network of digital-first primary care clinics and medical clinics that provide elective surgery. Visit www.thinkresearch.com for more details.

About Beedie Capital

Beedie Capital is a multi-strategy direct investment platform that manages the alternative investments for Beedie, one of the largest private companies in Western Canada. It deploys capital using a flexible, evergreen mandate, and applies a highly agnostic approach to the duration, structure and size of its investments. Beedie Capital combines the strategic capabilities of an institutional investment platform with the flexibility and entrepreneurial mindset of a privately owned business. Beedie Capital invests in any sector, with a core focus on Technology, Tech-enabled Services, and Metals and Mining, and seeks to grow its invested capital alongside the enterprise value of its investments. For further information on Beedie Capital, please visit www.beediecapital.com .

For further information, please contact:

Mark Sakamoto Executive Vice President Think Research Corporation Direct: 416-388-7119 [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Think Research

View the original press release on accesswire.com

Recommended Stories

Weʼre unable to load stories right now.

Digitize documentation and streamline your admissions workflow

Overcome barriers with tools and solutions made for efficiency and best-practice.

Think Research empowers long term post acute care homes and healthcare organizations to provide exceptional service and care while exceeding performance targets .

Our products are made for improved efficiency in day-to-day operations , including key tasks such as admissions and documentation. Integrated clinical content reduces variance in decision-making, improving outcomes with resident- and patient-centred care that also reduces costs.

eForms for Seniors Care

eForms replaces paper forms with a comprehensive digital documentation solution that lets long term post acute care organizations easily capture information while unlocking workflow efficiencies.

Streamline your admissions, reduce completion times and error rates, expedite consent capture, and strengthen compliance while reducing costs.

Used by over 500 organizations in 38 states, eForms is compatible with PointClickCare, MatrixCare and other systems.

Key features

• Remote digital signature capture, sharing, and form review with DocuSign integration
• Quick and easy-to-complete web-based electronic forms
• Form prepopulation using structured data from electronic health records
• Turn paper-based forms into questions and prompts that are easy to answer

Simplify and streamline your paper-based processes

• Embed content into forms tailored to your needs, ensuring fields are complete, accurate, and the right steps are followed
• Expand your operational insights with eForms’ structured data capabilities
• Get up and running within three months, not the usual 6 to 12, with hands-on assistance from our client success team
• Build compliance management across your organization through version control, required fields, and form data pre-population.

Think Research is proud to be a member of the California Association of Health Facilities  and the  Massachusetts Senior Care Association .

Product Brochure:  eForms

Case Study : How National HealthCare Corporation Modernized Admissions with eForms

Product Feature Comparisons – See how eForms compares against PointClickCare and DocuSign.

On-Demand Webinar – How eForms Can Digitize Long Term and Post Acute Care Admissions Paperwork

Spotlight is a comprehensive analytics tool for eForms that provides actionable insights for better decision-making.

Spotlight displays relevant data and let you tell complex stories and uncover hidden trends and bottlenecks.

• Combine aggregated data from multiple systems, including EHRs or third-party applications
• Customized dashboards deliver data aligned to your metrics, helping you make evidence-based decisions
• Manage and house data from a variety of sources to standardize care delivery and make insights accessible

The insight you need for better decisions

• Get insight into your operations and make the right decisions based on data
• Improve workflows and drive continuous improvement by leveraging your existing data to gain fresh insights
• Spotlight empowers you with the embedded clinical terminology, including SNOMED CT, ICD, CPT, or payer model terminologies like DRG

About Think Research

Think Research is a clinical content and technology company based in Toronto, Canada. We’re on a mission to structure the world’s healthcare knowledge and deliver it via connected technology solutions that make doing the right thing for your patients easy.

We’re proud to advance digital healthcare through our clinical standardization solutions, which remove barriers to outstanding care.

Since our founding in 2006 by critical care clinician Dr. Chris O’Connor, we’ve grown to support over 2,200 client partners in delivering exceptional care on three continents.

Accessibility | Privacy Policy

Register to View eForms Webinar

• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. View our full privacy and cookie policies.

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

This website uses Google Analytics and other tools to collect anonymous visitor information.

Please enable Strictly Necessary Cookies first so that we can save your preferences!